Drugs / CKD-381
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04830930 | Apr → Jun 2021 | gastroesophageal reflux disease | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT03558425 | Jun → Sep 2018 | gastroesophageal reflux disease | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT03444402 | Mar → May 2018 | gastroesophageal reflux disease | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT03211143 | Jun → Aug 2017 | gastroesophageal reflux disease | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CKD-381 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03211143 ↗ |
| Route | Oral | “oral administration” NCT04830930 ↗ |